mianserin has been researched along with Amphetamine-Related Disorders in 6 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Amphetamine-Related Disorders: Disorders related or resulting from use of amphetamines.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Modafinil-treated participants had a milder withdrawal syndrome as measured by the Amphetamine Cessation Symptom Assessment and less sleep disturbance in comparison to mirtazapine." | 2.73 | Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. ( McGregor, C; Mitchell, A; Srisurapanont, M; White, JM; Wickes, W, 2008) |
| "Mirtazapine safety was assessed by interview during each follow-up period on days 3 and 14 after treatment." | 2.71 | Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study. ( Kongsakon, R; Papadopoulos, KI; Saguansiritham, R, 2005) |
| "Priapism is a "persistent erection not accompanied by sexual desire or stimulation, usually lasting more than six hours and typically involving only the corpora cavernosa." | 1.33 | Priapism and quetiapine: a case report. ( Dilley, JW; Harrison, G; Loeb, L; Nelson, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hermanstyne, KA | 1 |
| Santos, GM | 2 |
| Vittinghoff, E | 2 |
| Santos, D | 1 |
| Colfax, G | 1 |
| Coffin, P | 1 |
| Colfax, GN | 1 |
| Das, M | 1 |
| Santos, DM | 1 |
| Matheson, T | 1 |
| Gasper, J | 1 |
| Shoptaw, S | 1 |
| Kongsakon, R | 1 |
| Papadopoulos, KI | 1 |
| Saguansiritham, R | 1 |
| Harrison, G | 1 |
| Dilley, JW | 1 |
| Loeb, L | 1 |
| Nelson, K | 1 |
| McGregor, C | 1 |
| Srisurapanont, M | 1 |
| Mitchell, A | 1 |
| Wickes, W | 1 |
| White, JM | 1 |
| Cruickshank, CC | 1 |
| Montebello, ME | 1 |
| Dyer, KR | 1 |
| Quigley, A | 1 |
| Blaszczyk, J | 1 |
| Tomkins, S | 1 |
| Shand, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors[NCT00497081] | Phase 2 | 60 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Treatment With Lorcaserin for Cocaine Use: The TLC Study[NCT03192995] | Phase 2 | 22 participants (Actual) | Interventional | 2018-01-01 | Terminated (stopped due to FDA alert regarding study drug safety) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00497081)
Timeframe: Baseline (week 0) and Final Visit (week 12)
| Intervention | Percentage reduction (Number) |
|---|---|
| Active Comparator: | 40 |
| Placebo Comparator: | 6 |
(NCT00497081)
Timeframe: From Baseline (week 0) through Final Visit (week 12)
| Intervention | Adverse Events Reported (Number) |
|---|---|
| Active Comparator: | 109 |
| Placebo Comparator: | 107 |
Proportion of days with recorded pill bottle opening, as determined by MEMS (medication event monitoring system). (NCT00497081)
Timeframe: Daily, from Baseline (week 0) through Final Visit (week 12)
| Intervention | Percentage of recorded openings (Mean) |
|---|---|
| Active Comparator: | 48.3 |
| Placebo Comparator: | 48.7 |
To evaluate the adherence of lorcaserin vs. placebo, the investigators measured adherence as the frequency of taking the study drug as measured by the number of MEMS cap openings (wireless medication monitoring devices that record each opening as a real-time medication event). Cumulative percent adherence was calculated by dividing the frequency of openings at a given time point divided by the number of days since baseline. (NCT03192995)
Timeframe: 12 weeks
| Intervention | percent adherence (Mean) |
|---|---|
| Experimental | 51.6 |
| Control | 66.2 |
To determine the feasibility of retaining individuals on lorcaserin vs. placebo, the investigators have calculated the mean weekly percentage of follow-up visits of those randomized in the study (NCT03192995)
Timeframe: 12 weeks
| Intervention | mean percent of visit retention (Mean) | |
|---|---|---|
| Treatment Group | Control Group | |
| Mean Percent of Weekly Follow-up Visits by Treatment and Control Arms | 83 | 81 |
The outcome measure determines the proportion of self-reported past week cocaine use by Time-Line-Follow-back (TLFB) among lorcaserin and placebo groups at Baseline and at 12 weeks. (NCT03192995)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Proportion of self-reported weekly cocaine use by Time-Line-Follow-Up (TLFU) at baseline | Proportion of self-reported weekly cocaine use by TLFU at Week 12 | |
| Control | 6 | 6 |
| Experimental | 12 | 7 |
The outcome measure determines the proportion of urine-positive samples with cocaine positivity among lorcaserin and placebo groups at Baseline and at Week 12 (NCT03192995)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Urine positive samples with cocaine use at baseline | Urine positive samples with cocaine use at Week 12 | |
| Control | 0 | 1 |
| Treatment | 8 | 7 |
5 trials available for mianserin and Amphetamine-Related Disorders
| Article | Year |
|---|---|
Event-level relationship between methamphetamine use significantly associated with non-adherence to pharmacologic trial medications in event-level analyses.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Bupropion; Female; Humans; Logistic Models; Male; | 2014 |
Mirtazapine to reduce methamphetamine use: a randomized controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Amphetamine-Related Disorders; Central Nervous System Stimulant | 2011 |
Mirtazapine to reduce methamphetamine use: a randomized controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Amphetamine-Related Disorders; Central Nervous System Stimulant | 2011 |
Mirtazapine to reduce methamphetamine use: a randomized controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Amphetamine-Related Disorders; Central Nervous System Stimulant | 2011 |
Mirtazapine to reduce methamphetamine use: a randomized controlled trial.
Topics: Adrenergic alpha-Antagonists; Adult; Amphetamine-Related Disorders; Central Nervous System Stimulant | 2011 |
Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Anxiety; Arousal | 2005 |
Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual.
Topics: Adult; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Centra | 2008 |
A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
Topics: Adult; Ambulatory Care; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Central Ner | 2008 |
1 other study available for mianserin and Amphetamine-Related Disorders
| Article | Year |
|---|---|
Priapism and quetiapine: a case report.
Topics: Amphetamine; Amphetamine-Related Disorders; Antipsychotic Agents; Comorbidity; Depressive Disorder; | 2006 |